When we think about overcoming coronavirus, we look to large pharmaceutical companies as one of the key players to get us back to normal.
healthcare
IMF global growth downgrade not hurting all businesses, says Insync FM
“The slowdown in the global economy will have relatively minimal impact on the outlook for Medtronics which is benefitting from the powerful megatrend in the growing demand for healthcare products and services and through innovation,” said Monik Kotecha, CIO, Insync Funds Management. In a low global growth environment, Insync is still finding opportunities in the […]
The Silver Economy shines for long-term growth in portfolios
While Australians can invest in some excellent local healthcare companies, there are limitations. For instance, they tend to be either single or narrow product device companies, says Monik Kotecha, Insync. Global pharmaceutical companies benefit from ageing demographics By 2005, 10 per cent of global population was aged over 60 By 2050, 22 per cent of […]
Insync invests in global biotech company Thermo Fisher
Insync Global Titans Fund has invested in global biotechnology company Thermo Fisher Scientific on an attractive free cash flow yield of 5.7 per cent for 2016. Ageing populations, the need for better and broader healthcare access globally, more stringent environmental and testing regulations, along with the rising demand for better healthcare and a cleaner environment […]